Rs 12 Dividend To Be Payable In August: Lupin Fixed July 25 As Record Date; Is The Blue Chip Stock A Buy?

With its headquarters located in Mumbai, India, Lupin Limited is a leading pharmaceutical company with pharmaceuticals supplied in more than 100 countries worldwide. The record date for the final dividend of Rs 12/- per equity share of Rs 2/- each (i.e. 600%) for FY25 has been announced by the blue-chip pharmaceutical company that is included on the BSE 100 index and has a market capitalization of Rs 89,120 Cr. See the trading guidelines and all the information about dividend payments here.

Lupin Dividend

"We are pleased to inform that the Forty-Third Annual General Meeting ('AGM') of the Company is scheduled to be held on Monday, August 11, 2025 at 04.00 p.m. (IST) through Video Conferencing/ Other Audio Visual Means. Other relevant details are being provided in the Notice of AGM, which will be issued in due course of time," said the company in a stock exchange filing.

The Board of Directors at its meeting held on Wednesday, May 14, 2025, had recommended a final Dividend of Rs 12/- per equity share of Rs 2/- each (i.e. 600%). Pursuant to Regulation 42 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company has fixed the record date for the purpose of determining the entitlement of members to receive the final dividend as Friday, July 25, 2025, as per a regulatory filing.

Lupin News

Recently on July 9, Zentiva Group (Zentiva), a pan-European pharmaceutical firm, and Lupin Limited (Lupin), a prominent global pharmaceutical company, signed a licensing and supply agreement for the marketing of Lupin's biosimilar Certolizumab Pegol across multiple international markets. Through this collaborative partnership, patients throughout the world will have quicker access to high-quality, reasonably priced biosimilar Certolizumab Pegol. Following the agreement's completion, Lupin will receive an initial payment of USD 10 million, with the remaining USD 50 million going toward development and regulatory milestone payments.

"Our global development and commercialization partnership with Zentiva, with its panEuropean focus, enables Lupin to commercialize this unique biosimilar in its core markets and through Zentiva in Europe," said Fabrice Egros, President of Corporate Development, Lupin. "This partnership underscores our dedication to improving the quality of life for individuals living with chronic conditions and ensuring accessibility and affordability of transformative therapies worldwide."

Lupin Share Price Target

"Lupin continues to trade with bullish strength after a steady rally. The stock has strong support at ₹1,880, and immediate resistance is placed at ₹1,975. A breakout above ₹1,975 can lead to a move toward ₹2,050. Price structure remains firm, supported by healthy volume and positive momentum indicators. The trend remains constructive as long as it holds above ₹1,880," commented Riyank Arora, technical analyst at Mehta Equities Ltd.

Disclaimer

The recommendations made above are by market analysts and are not advised by either the author, nor Greynium Information Technologies. The author, nor the brokerage firm nor Greynium would be liable for any losses caused as a result of decisions based on this write-up. Goodreturns.in advises users to consult with certified experts before making any investment decision.